Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Blood Coagul Fibrinolysis ; 17(8): 673-5, 2006 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-17102655

RESUMEN

Spontaneous bleeding in adults is a major problem, and in a significant number of these patients no cause is found. A 63-year-old Caucasian man presented to our hematology clinic with a large hematoma of his left thigh. Initial investigations did not show any conclusive abnormalities of primary or secondary hemostasis. Subsequent tests demonstrated a type 1 deficiency of antiplasmin. Treatment with low doses of epsilon-aminocaproic acid resulted in resolution of the hematoma and control of bleeding. We sought to determine the cause of the patient's isolated antiplasmin deficiency but no explanation was found. Three heterozygous polymorphisms were identified in his antiplasmin gene, ruling out major gene deletions. Each of these three polymorphisms has been previously reported in healthy blood donors. Finally, since response to antifibrinolytics can be dramatic, deficiencies of antiplasmin must be considered in patients presenting at any age with a spontaneous bleeding disorder.


Asunto(s)
Trastornos de la Coagulación Sanguínea/diagnóstico , Hematoma/sangre , alfa 2-Antiplasmina/metabolismo , Aminocaproatos/uso terapéutico , Antifibrinolíticos/uso terapéutico , Hematoma/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , alfa 2-Antiplasmina/genética
2.
Head Neck ; 31(9): 1144-51, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19340861

RESUMEN

BACKGROUND: This article reviews our community cancer center's experience treating head and neck cancer primarily with accelerated fractionation intensity-modulated radiation therapy (IMRT), with or without concurrent chemotherapy, focusing on acute toxicity and efficacy. METHODS: Fifty-two patients treated with IMRT at the Penrose Cancer Center between 2002 and 2007 constitute the cohort. The majority (75%) received an accelerated, altered fractionation regimen, typically concomitant boost to 7200 cGy. Concurrent chemotherapy was delivered to 32 (62%). The median follow-up was 24 months. RESULTS: The 2-year actuarial rates of local control, regional control, and distant metastasis-free survival were 100%, 91%, and 94%, respectively. Relapse-free survival and overall survival at 2 years were 89% and 91%, respectively. Overall, 32 of 52 patients (62%) experienced at least 1 type of grade 3 or 4 acute toxicity. CONCLUSION: Accelerated fractionation IMRT, with or without chemotherapy, can be given safely and effectively in a community cancer center setting.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Células Escamosas/radioterapia , Fraccionamiento de la Dosis de Radiación , Neoplasias de Oído, Nariz y Garganta/radioterapia , Radioterapia de Intensidad Modulada , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Células Escamosas/tratamiento farmacológico , Carcinoma de Células Escamosas/secundario , Terapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias de Oído, Nariz y Garganta/tratamiento farmacológico , Neoplasias de Oído, Nariz y Garganta/patología , Radioterapia de Intensidad Modulada/efectos adversos , Radioterapia de Intensidad Modulada/métodos , Estomatitis/etiología , Análisis de Supervivencia
3.
Am J Hematol ; 82(7): 625-30, 2007 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-17236184

RESUMEN

Copper deficiency is a recognized but often overlooked cause of anemia and neutropenia. We began checking serum copper levels on patients referred for evaluation for unexplained anemia and neutropenia or myelodysplasia. Eight patients were identified as copper deficient (serum copper less than 70 microg/dL). The anemia was normochromic and normocytic in seven patients. Neutropenia was present in seven patients. Seven patients had been referred for evaluation of myelodysplasia. Three were seen for consideration for allogenic stem cell transplant. Five patients had concomitant peripheral neurological symptoms. Seven patients were treated with oral copper gluconate. All treated patients demonstrated a hematological response; seven had a complete remission. The improvement in anemia and neutropenia was rapid with normalization of blood counts within three to four weeks. In one patient, normalization of the underlying marrow dysplasia was demonstrated by bone marrow histology eight months after copper replacement. The cause of copper deficiency was felt to be gastrointestinal malabsorption in five of our patients. We conclude that copper deficiency should be considered in all patients with unexplained anemia and neutropenia or myelodysplasia.


Asunto(s)
Cobre/deficiencia , Síndromes Mielodisplásicos/metabolismo , Síndromes Mielodisplásicos/patología , Adulto , Anciano , Cobre/metabolismo , Femenino , Hemoglobinas/metabolismo , Humanos , Recuento de Linfocitos , Persona de Mediana Edad , Síndromes Mielodisplásicos/etiología , Neutrófilos/citología
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda